These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 37099986)

  • 1. Impact of sarcopenia indexes on survival and severe immune acute toxicity in metastatic non-small cell lung cancer patients treated with PD-1 immune checkpoint inhibitors.
    Ashton E; Arrondeau J; Jouinot A; Boudou-Rouquette P; Hirsch L; Huillard O; Ulmann G; Lupo-Mansuet A; Damotte D; Wislez M; Alifano M; Alexandre J; Goldwasser F
    Clin Nutr; 2023 Jun; 42(6):944-953. PubMed ID: 37099986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new index based on serum creatinine and cystatin C is useful for assessing sarcopenia in patients with advanced cancer.
    Fu X; Tian Z; Wen S; Sun H; Thapa S; Xiong H; Liu H; Li L; Yu S
    Nutrition; 2021 Feb; 82():111032. PubMed ID: 33172686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum creatinine and cystatin C-based diagnostic indices for sarcopenia in advanced non-small cell lung cancer.
    Tang T; Xie L; Hu S; Tan L; Lei X; Luo X; Yang L; Yang M
    J Cachexia Sarcopenia Muscle; 2022 Jun; 13(3):1800-1810. PubMed ID: 35297568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Baseline Sarcopenia Index in Predicting Chemotherapy-Induced Undesirable Effects and Mortality in Older People with Stage III or IV Non-Small Cell Lung Cancer.
    Chen X; Hou L; Shen Y; Wu X; Dong B; Hao Q
    J Nutr Health Aging; 2021; 25(7):878-882. PubMed ID: 34409965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
    Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors.
    Roch B; Coffy A; Jean-Baptiste S; Palaysi E; Daures JP; Pujol JL; Bommart S
    Lung Cancer; 2020 May; 143():19-26. PubMed ID: 32200137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
    Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
    JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Real-world study on the efficacy and prognostic predictive biomarker of patients with metastatic non-small cell lung cancer treated with programmed death-1/programmed death ligand 1 inhibitors].
    Zhu WJ; Zhu HH; Liu YT; Lin L; Xing PY; Hao XZ; Cong MH; Wang HY; Wang Y; Li JL; Feng Y; Hu XS
    Zhonghua Zhong Liu Za Zhi; 2022 May; 44(5):416-424. PubMed ID: 35615798
    [No Abstract]   [Full Text] [Related]  

  • 9. Value of Cystatin C-Based Sarcopenia Index in Patients Undergoing Surgery for Renal Tumors.
    Yajima S; Nakanishi Y; Ogasawara RA; Imasato N; Hirose K; Katsumura S; Kataoka M; Masuda H
    Clin Genitourin Cancer; 2024 Jun; 22(3):102051. PubMed ID: 38423930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic accuracy of a 'sarcopenia index' based on serum biomarkers creatinine and cystatin C in 458,702 UK Biobank participants.
    Wilkinson TJ; Baker LA; Watson EL; Smith AC; Yates T
    Clin Nutr ESPEN; 2024 Oct; 63():207-213. PubMed ID: 38968079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low glomerular filtration rate as an associated risk factor for sarcopenic muscle strength: is creatinine or cystatin C-based estimation more relevant?
    Tufan A; Tufan F; Akpinar TS; Ilhan B; Bahat G; Karan MA
    Aging Male; 2017 Jun; 20(2):110-114. PubMed ID: 27650550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thyroid function abnormality induced by PD-1 inhibitors have a positive impact on survival in patients with non-small cell lung cancer.
    Zhou Y; Xia R; Xiao H; Pu D; Long Y; Ding Z; Liu J; Ma X
    Int Immunopharmacol; 2021 Feb; 91():107296. PubMed ID: 33360368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between the creatinine/cystatin C ratio and muscle mass measured by CT-scan in cancer patients.
    Tlemsani C; Durand JP; Raynard B; Revel MP; Deluche E; Di Palma M; Pigneur F; Goldwasser F
    Clin Nutr ESPEN; 2022 Oct; 51():412-418. PubMed ID: 36184236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer.
    Abedian Kalkhoran H; Zwaveling J; Storm BN; van Laar SA; Portielje JE; Codrington H; Luijten D; Brocken P; Smit EF; Visser LE
    BMC Cancer; 2023 Mar; 23(1):247. PubMed ID: 36918817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive impact of sarcopenia in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: A retrospective study.
    Feng Y; Wang L; Guo F; Zhu F; Shi J; Wang Y; Zhang Y; Chen X; Zhang L
    Heliyon; 2024 Mar; 10(5):e27282. PubMed ID: 38463845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weighing the role of skeletal muscle mass and muscle density in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: a multicenter real-life study.
    Cortellini A; Bozzetti F; Palumbo P; Brocco D; Di Marino P; Tinari N; De Tursi M; Agostinelli V; Patruno L; Valdesi C; Mereu M; Verna L; Lanfiuti Baldi P; Venditti O; Cannita K; Masciocchi C; Barile A; McQuade JL; Ficorella C; Porzio G
    Sci Rep; 2020 Jan; 10(1):1456. PubMed ID: 31996766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune-related adverse events of a PD-L1 inhibitor plus chemotherapy versus a PD-L1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials.
    Wang M; Liang H; Wang W; Zhao S; Cai X; Zhao Y; Li C; Cheng B; Xiong S; Li J; He J; Liang W
    Cancer; 2021 Mar; 127(5):777-786. PubMed ID: 33119182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
    JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between immune-related adverse events and the efficacy of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: systematic review and meta-analysis.
    Zhang Q; Wang W; Yuan Q; Li L; Wang YC; Chi CZ; Xu CH
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):1-9. PubMed ID: 34821962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for immune-related adverse events from anti-PD-1 or anti-PD-L1 treatment in an Asian cohort of nonsmall cell lung cancer patients.
    Huang Y; Soon YY; Aminkeng F; Tay SH; Ang Y; Kee ACL; Goh BC; Wong ASC; Soo RA
    Int J Cancer; 2022 Feb; 150(4):636-644. PubMed ID: 34562273
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.